You are here: Geisinger Medical
Laboratories > Test
Catalog
Geisinger Medical Laboratories/Geisinger Proven Diagnostics Test Catalog
SUSPECTED TRANSFUSION REACTION EVALUATION AND INTERPRETATION |
||
ORDERING INFORMATION: |
Geisinger Epic Procedure Code: LAB3106 Geisinger Epic ID: 26822 | |
SPECIMEN COLLECTION |
||
Specimen type: |
Whole blood | |
Preferred collection container: |
||
Specimen required: |
6 mL whole blood | |
Special notes: |
Specimen must be labeled with patient's first and last name, medical record number or some unique other identifier (e.g.,billing number, NOT date of birth). Date of collection and phlebotomist identification (full name or tech ID) must be available. Positive patient identification must be assured. | |
| SPECIMEN PROCESSING |
||
Specimen processing instructions: |
Do not centrifuge or aliquot. | |
Transport temperature: |
Preferred specimen: Room temperature (less than 24 hours). If greater than 24 hours, specimen should be stored at 2-8°C. | |
Specimen stability: |
Specimen must be less than 48 hours old for testing. | |
Rejection criteria: |
Tube containing gel separator. Incomplete label ID (see specimen collection note). | |
TEST DETAILS |
||
Critical values/courtesy alerts: |
Hemolysis (courtesy alert to pathologist on call). | |
Additional information: |
Immediately return bag with any remaining blood product, along with any tubing or solution running in conjunction with the blood and completed transfusion reaction flowsheet to the Blood Bank. | |
CPT code(s): |
86078 | |
| Note: The billing party has sole responsibility for CPT coding. Any questions regarding coding should be directed to the payer being billed. The CPT codes provided by GML are based on AMA guidelines and are for informational purposes only. | ||
Test includes: |
May include ABO/Rh, Antibody Screen, Direct Coombs. | |
Methodology: |
RBC agglutination and/or gel column technology |
|
Synonyms: |
Transfusion Reaction Workup
|
|
Clinical significance: |
Transfusion reaction workup is ordered to investigate when transfused components are suspected to be associated with adverse reactions in the patient. | |
Doctoral Director(s:) |
Randin Nelson MD | |
| Review Date: | 10/21/2022 | |
Performing Locations
Geisinger Wyoming Valley Medical Center